8-K: Caribou Biosciences Reports Promising Clinical Data and Financial Results for 2024

Caribou Biosciences announces positive clinical trial updates and financial results for Q4 and full year 2024, with cash runway extended into H2 2026.

Summary

• Caribou Biosciences reported its financial results for the fourth quarter and full year 2024 and provided a business update on March 10, 2025.
• The company anticipates presenting clinical data from the ANTLER Phase 1 trial of CB-010 in second-line large B cell lymphoma and initial data from the CaMMouflage Phase 1 trial of CB-011 in relapsed or refractory multiple myeloma in H1 2025.
• Caribou had $249.4 million in cash, cash equivalents, and marketable securities as of December 31, 2024, which is expected to fund operations into H2 2026.
• The company reported licensing and collaboration revenue of $2.1 million for Q4 2024 and $10.0 million for the full year 2024.
• Research and development expenses were $30.5 million for Q4 2024 and $130.2 million for the full year 2024.
• General and administrative expenses were $10.5 million for Q4 2024 and $46.5 million for the full year 2024.
• Caribou reported a net loss of $35.5 million for Q4 2024 and $149.1 million for the full year 2024.

Sentiment

Score: 7

Explanation: The sentiment is moderately positive due to promising clinical data, a strong cash position, and advancement of multiple clinical programs. However, increased net losses and decreased licensing revenue temper the overall outlook.

Positives

• The company has a strong cash position of $249.4 million, providing a runway into H2 2026.
• Clinical data for CB-010 shows potential to match the efficacy and safety of autologous CAR-T therapies.
• Encouraging signs of efficacy are observed in patients treated with CB-011 at active dose levels.
• The company is advancing four clinical programs for hematologic malignancies and autoimmune diseases.
• Caribou plans to initiate a pivotal Phase 3 clinical trial for CB-010 in H2 2025, pending FDA agreement.

Negatives

• The company reported a net loss of $149.1 million for the full year 2024, compared to a net loss of $102.1 million for the same period in 2023.
• Licensing and collaboration revenue decreased for the full year 2024, primarily due to the termination of the AbbVie Collaboration and License Agreement.

Risks

• The company's forward-looking statements are subject to risks and uncertainties, and actual results may differ materially.
• Risks are inherent in the development of cell therapy products.
• Uncertainties are related to the initiation, cost, timing, progress, and results of its current and future research and development programs, preclinical studies, and clinical trials.
• Initial, preliminary, or interim clinical trial data may not be predictive of the safety and efficacy of Caribou's product candidates.
• The company has a limited operating history and a history of net operating losses.

Future Outlook

Caribou anticipates presenting clinical data from multiple Phase 1 trials in H1 2025 and plans to initiate a pivotal Phase 3 trial for CB-010 in H2 2025, pending FDA agreement. The company expects its current cash reserves to fund operations into H2 2026.

Management Comments

• Caribou is planning for two clinical data disclosures in the first half of 2025 as we advance the development of our off-the-shelf CAR-T cell therapies in oncology and autoimmune diseases, said Rachel Haurwitz, PhD, Caribous president and chief executive officer.
• We expect to present data from the ANTLER Phase 1 trial of CB-010 in patients with second-line large B cell lymphoma and our goal for this program is to develop an allogeneic CAR-T cell therapy that can drive outcomes on par with those achieved by autologous CAR-T cell therapies.
• We also expect to present initial data from the CaMMouflage Phase 1 trial of CB-011 in patients with relapsed or refractory multiple myeloma.
• As we rapidly enroll additional patients in CaMMouflage, we continue to observe encouraging signs of efficacy in patients treated with CB-011 at active dose levels following a deeper lymphodepletion regimen.
• We are excited to be at the forefront of a new era of allogeneic CAR-T cell therapies that offer the potential for broad access and rapid availability to both patients and healthcare systems.
• Working with Steve over the last eight years has been a privilege.
• His lasting legacy is evident in the strong, expert bench of scientific leaders who will continue to advance our technologies.
• Steve is a talented scientist.
• His leadership has been critical to the development of our off-the-shelf CAR-T cell therapy technologies and to the development of our clinical pipeline.
• On behalf of the entire herd at Caribou, I would like to express my gratitude for his significant contributions, and I wish him the best in his well-deserved retirement following a four-decade career.

Industry Context

Caribou Biosciences is operating in the competitive field of CRISPR genome-editing and allogeneic CAR-T cell therapies. The company's focus on off-the-shelf therapies aims to address the limitations of autologous CAR-T therapies, such as manufacturing complexity and patient-specific production. The progress of clinical trials and financial stability are crucial for maintaining a competitive edge in this rapidly evolving market.

Comparison to Industry Standards

• Caribou's CB-010 aims to achieve efficacy on par with autologous CAR-T therapies like Novartis's Kymriah and Gilead's Yescarta, which have shown significant success in treating certain B-cell lymphomas.
• The company's allogeneic approach is similar to that of other companies like Allogene Therapeutics and CRISPR Therapeutics, which are also developing off-the-shelf CAR-T therapies to overcome the limitations of autologous treatments.
• Caribou's cash runway into H2 2026 is comparable to other biotech companies at a similar stage of development, providing financial stability for ongoing clinical trials and research activities.
• The company's focus on HLA matching in CB-010 is a strategy to improve persistence and reduce rejection, similar to approaches being explored by other companies in the allogeneic CAR-T space.

Management Changes

Legal Proceedings

• General and administrative expenses increased for the year ended December 31, 2024, primarily due to legal expenses and other service-related expenses, including litigation settlement costs.

Stakeholder Impact

• Shareholders: The clinical progress and financial stability are positive for shareholders.
• Employees: The retirement of the CSO and subsequent advisory role may impact research and development initiatives.
• Patients: Advancing clinical trials offer potential new treatment options for patients with hematologic malignancies and autoimmune diseases.
• Healthcare Systems: The development of allogeneic CAR-T cell therapies could provide broader access and rapid availability of treatments.

Next Steps

• Present data from the ANTLER Phase 1 clinical trial of CB-010 in 2L LBCL and prior CD19 relapsed LBCL patient cohorts in H1 2025.
• Present dose escalation data from the CaMMouflage Phase 1 clinical trial of CB-011 in r/r MM in H1 2025.
• Provide updates on dose escalation from the AMpLify Phase 1 clinical trial for CB-012.
• Provide updates from the GALLOP Phase 1 clinical trial for CB-010 in patients with LN and ERL.
• Initiate a pivotal Phase 3 clinical trial for CB-010 in H2 2025, pending FDA agreement.

Key Dates